Urogen Pharma ( (URGN) ) has released its Q3 earnings. Here is a breakdown of the information Urogen Pharma presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
UroGen Pharma Ltd., a biotechnology company, focuses on developing innovative treatments for urothelial and specialty cancers using its proprietary RTGel® technology. In its third-quarter 2025 earnings report, UroGen highlighted the successful launch of ZUSDURI, the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and reported a net product revenue of $1.8 million for ZUSDURI in its first quarter on the market. The company also achieved $25.7 million in net product revenue for JELMYTO, reflecting a 13% year-over-year growth. UroGen’s financial position remains strong with $127.4 million in cash and equivalents, despite a net loss of $33.3 million for the quarter. The company is optimistic about the commercial potential of ZUSDURI, supported by strong patient demand and broad reimbursement coverage. Looking ahead, UroGen plans to submit a New Drug Application for UGN-103 in 2026, aiming for approval in 2027, and continues to advance its pipeline to deliver long-term value for patients and shareholders.